Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model

Podobne knjige/članki

• HRAS Mutations and Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Head and Neck Squamous Cell Carcinoma Cells
  od: Hah, J. Hun, et al.
  Izdano: (2014)
• Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells’ Sensitivity to Cisplatin and Radiation In Vivo and In Vitro
  od: Sano, Daisuke, et al.
  Izdano: (2011)
• Xenograft models of head and neck cancers
  od: Sano, Daisuke, et al.
  Izdano: (2009)
• Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma
  od: Klein, Jonah D., et al.
  Izdano: (2012)
• Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma
  od: Papadimitrakopoulou, VA, et al.
  Izdano: (2015)